C
Circle Pharma
Early stage biotechnology company applying proprietary
About Circle Pharma
Circle Pharma is a biotechnology company focused on developing innovative macrocyclic peptide therapeutics to address challenging intracellular targets, particularly in oncology. The company operates in the pharmaceutical and biotechnology market, serving clients such as pharmaceutical companies and research institutions. Circle Pharma's business model revolves around its proprietary discovery engine, which combines computational structure-based design with automated synthetic chemistry to create cell-permeable macrocycles. These macrocycles are designed to target protein-protein interactions that are critical in cancer but have been difficult to address with traditional small molecule drugs. The company generates revenue through collaborations, partnerships, and licensing agreements with major pharmaceutical companies. Circle Pharma's approach leverages advanced computational techniques to screen large virtual libraries of macrocycles, ensuring high target affinity and cell permeability. This innovative method allows the company to develop therapeutics with significant clinical and commercial potential. Keywords: macrocyclic peptides, oncology, intracellular targets, computational design, synthetic chemistry, protein-protein interactions, biotechnology, pharmaceutical, cell permeability, drug discovery.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- South San Francisco, United States
- Employees
- 68
- Open positions
- None listed
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Circle Pharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2024 | $90M | $360M | Nextech Invest · Euclidean Capital · The Column Group | ↗ |
| SERIES COther financing | Jun 2021 | $66M | $264M | Pavillion Capital · Euclidean Capital · Eli Lilly · Pandect Bioventures | — |
Growth signals
Latest recorded traffic for Circle Pharma is 3.7K monthly website visits, up 76.2% over the last three months. Circle Pharma's team declined 6.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Mission Bay Capital
Pfizer
Series A6 investors entered at this stage
ShangPharma
WI Harper Group- EPElement Partners
Lifeforce Capital
The Column Group
Nextech Invest
Series B and later5 investors entered at this stage
Pavillion Capital- ECEuclidean Capital
Eli Lilly
Pandect Bioventures
Hartford HealthCare Endowment
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Circle Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circle Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.